Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
Exploratory Study of Efficacy and Safety of Different Administration Routes of SHR-A1811 in Patients With HER2-Positive Advanced Breast Cancer
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Tianjin, Porcelana, 300060
- Tianjin Medical University Cancer Insititute and Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Aged ≥ 18 years old.
- Pathologically confirmed HER2-positive advanced breast cancer. HER2 positivity is defined as IHC 3+ in >10% immunoreactive cells or HER2 gene amplification confirmed by in situ hybridization (ISH), which shall be verified by the pathology department of the participating center.
- Patients with advanced breast cancer who have received no more than 2 lines of prior systemic therapies.
- Expected survival time ≥ 4 months.
- Have at least one measurable lesion per RECIST 1.1 criteria (helical CT scan lesion diameter ≥ 10 mm with slice thickness ≤ 5 mm).
- Adequate major organ function without blood transfusion.
- Voluntarily participate in the study, sign informed consent form, with good compliance and willingness to complete follow-up visits.
Exclusion Criteria:
- Prior treatment with anti-HER2 antibody-drug conjugates (ADC).
- Known leptomeningeal metastasis or active brain metastasis.
- A history of other malignancies within the past 5 years, except for cured cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma. Malignancies cured solely by surgery more than 5 years prior to enrollment are allowed.
- Major surgery or severe trauma within 4 weeks before enrollment, or planned major surgery during the study period.
- Participation in other investigational new drug clinical trials within 4 weeks prior to enrollment.
- Presence of hereditary bleeding tendency or coagulation disorders.
- Uncontrolled hypertension with systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg despite standard antihypertensive therapy.
- A history of clinically significant pulmonary diseases, including but not limited to interstitial pneumonia, active pneumonia, pulmonary fibrosis and radiation pneumonitis (excluding asymptomatic post-radiation changes without treatment requirement).
- A history of severe cardiac diseases or uncontrolled cardiac conditions, including NYHA class II or higher cardiac insufficiency, unstable angina, myocardial infarction within one year, and arrhythmias requiring clinical intervention.
- Conditions affecting drug intake and absorption, such as dysphagia, chronic diarrhea and intestinal obstruction.
- Known allergy to any component of the study drugs.
- Uncontrolled pleural effusion or ascites that cannot be relieved by drainage or other clinical interventions.
- Severe uncontrolled comorbidities, including immune deficiency disorders (e.g. HIV positivity, history of organ transplantation), active hepatitis B or hepatitis C, and severe ongoing infections requiring systemic anti-infective treatment.
- Any other conditions considered inappropriate for study enrollment by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm 1: Weekly administration group
|
SHR-A1811 administered weekly
SHR-A1811 administered every two weeks (q2w)
SHR-A1811 administered every three weeks (q3w)
|
|
Experimental: Arm 2: Every-two-weeks (Q2W) administration group
|
SHR-A1811 administered weekly
SHR-A1811 administered every two weeks (q2w)
SHR-A1811 administered every three weeks (q3w)
|
|
Experimental: Arm 3: Every-three-weeks (Q3W) administration group
|
SHR-A1811 administered weekly
SHR-A1811 administered every two weeks (q2w)
SHR-A1811 administered every three weeks (q3w)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR)
Periodo de tiempo: From enrollment until disease progression or up to 2 years
|
Defined as the proportion of patients who achieve confirmed complete response (CR) or partial response (PR) to the study treatment, assessed per RECIST 1.1 criteria.
|
From enrollment until disease progression or up to 2 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Periodo de tiempo: From enrollment until disease progression or up to 2 years
|
Defined as the time from study enrollment to the first documentation of disease progression (per RECIST 1.1) or all-cause death, whichever occurs first.
|
From enrollment until disease progression or up to 2 years
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: From enrollment until all-cause death.
|
Defined as the time from study enrollment to all-cause death.
|
From enrollment until all-cause death.
|
|
Safety and Tolerability
Periodo de tiempo: From first dose of study drug up to 30 days after last dose
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
From first dose of study drug up to 30 days after last dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- MA-BC-II-145
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .